ROR1 is an Intriguing Target for Cancer Therapy

Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) is an oncofetal protein and has gained attention in cancer therapy since its initial discovery as a relatively specific surface antigen on B cell chronic lymphocytic leukemia (CLL) in 2008. The list of cancer types with ROR1 expression keeps growing, comprising, among others, malignant melanoma, breast cancer, and prostate cancer. It has been shown that ROR1 mediates several oncogenic pathways in a cancer type- and context-dependent manner. There are several ways to target ROR1 molecule, some of which have been in preclinical and clinical trials. We briefly summarize the oncogenic signaling pathways related to ROR1, as well as the update on ROR1-targeted therapies.

[1]  L. Giménez,et al.  ROR1 contributes to melanoma cell growth and migration by regulating N‐cadherin expression via the PI3K/Akt pathway , 2016, Molecular carcinogenesis.

[2]  J. Lambert,et al.  New developments for antibody-drug conjugate-based therapeutic approaches. , 2016, Current opinion in immunology.

[3]  Yu-Sun Chang,et al.  Expression of ROR1 has prognostic significance in triple negative breast cancer , 2016, Virchows Archiv.

[4]  G. Widhopf,et al.  Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. , 2015, The Journal of clinical investigation.

[5]  Young Chul Kim,et al.  Alternative Wnt Signaling Activates YAP/TAZ , 2015, Cell.

[6]  G. Widhopf,et al.  Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. , 2015, Clinical lymphoma, myeloma & leukemia.

[7]  A. I. Imani Fooladi,et al.  An In silico Chimeric Vaccine Targeting Breast Cancer Containing Inherent Adjuvant , 2015, Iranian journal of cancer prevention.

[8]  S. Riddell,et al.  Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells , 2014, Cancer Immunology Research.

[9]  N. Borcherding,et al.  ROR1, an embryonic protein with an emerging role in cancer biology , 2014, Protein & Cell.

[10]  F. de Marinis,et al.  ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. , 2014, Translational lung cancer research.

[11]  A. Weeraratna,et al.  Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. , 2013, Cancer discovery.

[12]  A. Porwit,et al.  Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies , 2013, Leukemia & lymphoma.

[13]  Terry P Yamaguchi,et al.  Wnt5a Potentiates TGF-β Signaling to Promote Colonic Crypt Regeneration After Tissue Injury , 2012, Science.

[14]  C. Turtle,et al.  Engineered T cells for anti-cancer therapy. , 2012, Current opinion in immunology.

[15]  W. Wilson,et al.  Targeting malignant B cells with an immunotoxin against ROR1 , 2012, mAbs.

[16]  Tomoya Yamaguchi,et al.  NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. , 2012, Cancer cell.

[17]  J. Wang-Rodriguez,et al.  ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth , 2012, PloS one.

[18]  K. Kwong,et al.  Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies , 2011, PloS one.

[19]  Thomas M. Schmitt,et al.  The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. , 2010, Blood.

[20]  Jeffrey P. MacKeigan,et al.  Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance , 2005, Nature Cell Biology.